F Stephen Hodi Selected Research

Antigens

1/2021	Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors.
1/2019	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
1/2018	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
1/2016	Landscape of tumor-infiltrating T cell repertoire of human cancers.
1/2016	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
1/2014	Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.
6/2013	Ipilimumab for patients with advanced mucosal melanoma.
5/2013	Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
3/2013	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
5/2012	Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

F Stephen Hodi Research Topics

Disease

190	Melanoma (Melanoma, Malignant) 12/2022 - 05/2002
177	Neoplasms (Cancer) 01/2022 - 05/2002
22	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 05/2002
21	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2002
20	Disease Progression 12/2021 - 05/2012
14	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 03/2013
12	Pneumonia (Pneumonitis) 01/2022 - 07/2015
12	Brain Neoplasms (Brain Tumor) 12/2021 - 05/2012
11	Colitis 01/2022 - 05/2012
9	Body Weight (Weight, Body) 10/2019 - 08/2010
7	Fatigue 01/2021 - 05/2012
7	Lung Neoplasms (Lung Cancer) 12/2016 - 03/2003
6	Uveal melanoma 01/2020 - 01/2012
5	Exanthema (Rash) 01/2022 - 05/2012
5	Hypophysitis 01/2022 - 11/2016
5	Hypothyroidism 01/2019 - 01/2014
4	Leukemia 12/2022 - 01/2006
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2003
4	Inflammation (Inflammations) 01/2020 - 03/2013
4	Lymphoma (Lymphomas) 01/2018 - 09/2002
3	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2022 - 07/2016
3	Triple Negative Breast Neoplasms 01/2022 - 01/2020
3	Adenocarcinoma of Lung 01/2021 - 08/2015
3	Ovarian Neoplasms (Ovarian Cancer) 11/2020 - 03/2003
3	Fever (Fevers) 01/2019 - 02/2015
3	Autoimmune Diseases (Autoimmune Disease) 02/2018 - 01/2006
3	Testicular Neoplasms (Testicular Cancer) 01/2016 - 05/2012
3	Necrosis 12/2010 - 04/2003
2	Infections 01/2022 - 03/2013
2	Hyponatremia 01/2022 - 08/2015
2	Hepatitis 01/2022 - 12/2020
2	Neurologic Manifestations (Neurological Manifestations) 11/2021 - 08/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 06/2012
2	Tics (Tic) 01/2021 - 01/2019
2	Thyrotoxicosis 01/2019 - 12/2017
2	Addison Disease (Addison's Disease) 01/2019 - 02/2018

Drug/Important Bio-Agent (IBA)

84	IpilimumabIBA 10/2022 - 09/2008
74	Immune Checkpoint InhibitorsIBA 05/2022 - 03/2013
45	NivolumabIBA 12/2022 - 04/2014
28	pembrolizumabIBA 01/2022 - 07/2013
22	AntigensIBA 01/2021 - 05/2002
20	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 05/2002
19	Monoclonal AntibodiesIBA 10/2019 - 09/2007
18	AntibodiesIBA 01/2020 - 05/2002
16	VaccinesIBA 12/2022 - 05/2002
16	LigandsIBA 01/2020 - 06/2006
16	Proteins (Proteins, Gene)FDA Link 08/2019 - 03/2003
15	CytokinesIBA 01/2022 - 12/2010
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2008
13	B7-H1 AntigenIBA 01/2022 - 11/2014
13	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2019 - 05/2010
12	Pharmaceutical PreparationsIBA 01/2019 - 05/2010
11	atezolizumabIBA 01/2022 - 07/2014
11	CTLA-4 AntigenIBA 10/2020 - 04/2003
10	Bevacizumab (Avastin)FDA Link 06/2021 - 01/2014
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 12/2010
10	VemurafenibIBA 01/2019 - 01/2012
8	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 04/2016
8	Biological ProductsIBA 10/2019 - 04/2003
8	Programmed Cell Death 1 ReceptorIBA 01/2019 - 03/2013
7	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2016
7	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 04/2008
6	trametinibIBA 01/2019 - 03/2013
6	dabrafenibIBA 01/2019 - 03/2013
5	InterferonsIBA 11/2021 - 01/2018
5	Interleukin-2 (IL2)IBA 10/2014 - 01/2006
4	PlatinumIBA 01/2021 - 06/2002
4	Complementary DNA (cDNA)IBA 06/2008 - 05/2002
4	Neoplasm Antigens (Tumor Antigens)IBA 04/2008 - 03/2003
3	Alanine Transaminase (SGPT)IBA 12/2021 - 04/2015
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2019
3	Protein Kinase CIBA 01/2020 - 01/2012
3	SurvivinIBA 08/2019 - 09/2012
3	EpitopesIBA 08/2019 - 11/2005
3	Insulin (Novolin)FDA Link 01/2019 - 04/2012
3	Immune Checkpoint ProteinsIBA 03/2018 - 02/2016
3	talimogene laherparepvecIBA 09/2017 - 01/2015
3	SuspensionsIBA 12/2016 - 02/2003
3	Glycoproteins (Glycoprotein)IBA 11/2016 - 08/2010
3	Codon (Codons)IBA 09/2012 - 01/2012
2	relatlimabIBA 12/2022 - 01/2022
2	SteroidsIBA 01/2022 - 01/2017
2	Histone Deacetylase InhibitorsIBA 12/2021 - 11/2016
2	ChemokinesIBA 11/2021 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021 - 01/2017
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 10/2018
2	Vitamin D FDA LinkGeneric 01/2020 - 01/2017
2	sotrastaurinIBA 01/2020 - 09/2012
2	Small Cytoplasmic RNAIBA 01/2020 - 11/2018
2	Peptide LibraryIBA 08/2019 - 01/2015
2	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2019 - 03/2018
2	CreatinineIBA 01/2019 - 01/2016
2	STA 9090IBA 12/2018 - 01/2013

Therapy/Procedure

120	Therapeutics 05/2022 - 01/2006
60	Immunotherapy 01/2022 - 01/2006
11	Drug Therapy (Chemotherapy) 01/2022 - 06/2002
11	Radiotherapy 01/2022 - 01/2014
4	Aftercare (After-Treatment) 01/2020 - 04/2014
3	Retreatment 12/2016 - 04/2013
2	Hematopoietic Stem Cell Transplantation 11/2021 - 07/2016